TXG
$69.86-3.50%
as of close, Oct 16, 2026
☾ AH $69.86 -3.50%
10x Genomics Inc.Stock · HealthcareRussell 2000 0.1%Nasdaq Composite 0.01%Russell 3000 0.006%US Stock Market 0.006%
TXG SEC filings (2026)
CIK 1770787 · Laboratory Analytical Instruments (SIC 3826) · incorporated in DE · fiscal year ends in December
694 filings on EDGAR since 2019 · 8 annual, 21 quarterly, 65 current · financial statements · earnings
Latest 10-K
Feb 13, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 7, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 6, 2026
10x Genomics Reports Second Quarter 2026 Financial Results
Last earnings release
Aug 6, 2026
−$0.14 vs −$0.23 · ▲ 14.1%
Filings on file
694
since 2019, 463 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 22Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 25,000 Class A shares for $2.0M at $78.23–$82.37 under a 10b5-1 plan
- Sep 22Insider saleSULIMAN SHEHNAAZ (Director) sold 5,723 Class A shares for $465K at $78.20–$82.28 under a 10b5-1 plan
- Sep 9Insider saleTaich Adam (Chief Financial Officer) sold 46,388 Class A shares for $3.0M at $63.68–$65.26 under a 10b5-1 plan
- Sep 3Insider saleSTUELPNAGEL JOHN R (Director) sold 20,000 Class A shares for $1.2M at $60.66–$62.61
August 2026
- Aug 26Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 10,486 Class A shares for $668K at $63.02–$64.75 under a 10b5-1 plan
- Aug 24Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 18,545 Class A shares for $1.2M at $63.02
- Aug 24Insider saleTaich Adam (Chief Financial Officer) sold 17,166 Class A shares for $1.1M at $63.02
- Aug 24Insider saleHindson Benjamin J. (See Remarks · Director) sold 13,818 Class A shares for $871K at $63.02
- Aug 24Insider saleSULIMAN SHEHNAAZ (Director) sold 2,207 Class A shares for $140K at $62.73–$63.97 under a 10b5-1 plan
- Aug 14Insider saleTeichmann Sarah A. (Director) sold 2,273 Class A shares for $130K at $57.15 under a 10b5-1 plan
- Aug 13Insider saleTeichmann Sarah A. (Director) sold 5,278 Class A shares for $302K at $57.29 under a 10b5-1 plan
- Aug 11Insider saleSTUELPNAGEL JOHN R (Director) sold 20,000 Class A shares for $1.2M at $57.58–$58.73
- Aug 7ReportQuarterly report, Q2 2026 — revenue $151.0M (−13% y/y), net income −$17.9M, EPS −$0.14
- Aug 6EarningsEarnings release — EPS −$0.14 vs −$0.23 est. (+39.1%); revenue $151.0M (−13% y/y) 14.1%
June 2026
May 2026
- May 26Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 10,718 Class A shares for $265K at $24.71 under a 10b5-1 plan
- May 22Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 18,175 Class A shares for $444K at $24.44 under a 10b5-1 plan
- May 22Insider saleTaich Adam (Chief Financial Officer) sold 15,098 Class A shares for $369K at $24.44
- May 22Insider saleHindson Benjamin J. (See Remarks · Director) sold 11,595 Class A shares for $283K at $24.44
- May 8ReportQuarterly report, Q1 2026 — revenue $150.8M (−3% y/y), net income −$13.5M, EPS −$0.10
- May 7EarningsEarnings release — EPS −$0.10 vs −$0.29 est. (+65.5%); revenue $150.8M (−3% y/y) 3.7%
April 2026
- Apr 24ProxyProxy · Additional proxy materials
- Apr 24ProxyProxy · Proxy statement
- Apr 14Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 5,000 Class A shares for $123K at $24.56 under a 10b5-1 plan
March 2026
- Mar 24Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 5,000 Class A shares for $98K at $19.52 under a 10b5-1 plan
- Mar 23Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 10,000 Class A shares for $191K at $19.13 under a 10b5-1 plan
- Mar 2Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 16,152 Class A shares for $367K at $22.67–$23.18 under a 10b5-1 plan
February 2026
- Feb 25Insider saleTeichmann Sarah A. (Director) sold 7,579 Class A shares for $147K at $19.41 under a 10b5-1 plan
- Feb 23Insider saleSaxonov Serge (Chief Executive Officer · Director) sold 9,632 Class A shares for $179K at $18.58
- Feb 23Insider saleTaich Adam (Chief Financial Officer) sold 8,968 Class A shares for $167K at $18.58
- Feb 23Insider saleHindson Benjamin J. (See Remarks · Director) sold 7,826 Class A shares for $145K at $18.58
- Feb 13ReportAnnual report, FY2025 — revenue $642.8M (+5% y/y), net income −$43.5M, EPS −$0.35
- Feb 12EarningsEarnings release — EPS −$0.13 vs −$0.19 est. (+31.6%); revenue $166.0M (+1% y/y) 3.5%
January 2026
- Jan 128-K8-K · 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 ResultsResults of operations
November 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $16.2M in 26 sales and bought nothing on the open market; 14 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 22, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $2.0M · 25,000 sh · 10b5-1 |
| Sep 22, 2026Form 4 | SULIMAN SHEHNAAZDirectorSold · Class A · $465K · 5,723 sh · 10b5-1 |
| Sep 9, 2026Form 4 | Taich AdamChief Financial OfficerSold · Class A · $3.0M · 46,388 sh · 10b5-1 |
| Sep 3, 2026Form 4 | STUELPNAGEL JOHN RDirectorSold · Class A · $1.2M · 20,000 sh |
| Aug 26, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $668K · 10,486 sh · 10b5-1 |
| Aug 24, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $1.2M · 18,545 sh |
| Aug 24, 2026Form 4 | Taich AdamChief Financial OfficerSold · Class A · $1.1M · 17,166 sh |
| Aug 24, 2026Form 4 | Hindson Benjamin J.See Remarks · DirectorSold · Class A · $871K · 13,818 sh |
| Aug 24, 2026Form 4 | SULIMAN SHEHNAAZDirectorSold · Class A · $140K · 2,207 sh · 10b5-1 |
| Aug 14, 2026Form 4 | Teichmann Sarah A.DirectorSold · Class A · $130K · 2,273 sh · 10b5-1 |
| Aug 13, 2026Form 4 | Teichmann Sarah A.DirectorSold · Class A · $302K · 5,278 sh · 10b5-1 |
| Aug 11, 2026Form 4 | STUELPNAGEL JOHN RDirectorSold · Class A · $1.2M · 20,000 sh |
| Jun 22, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $1.0M · 30,000 sh · 10b5-1 |
| Jun 16, 2026Form 4 | SULIMAN SHEHNAAZDirectorSold · Class A · $187K · 5,723 sh · 10b5-1 |
| May 26, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $265K · 10,718 sh · 10b5-1 |
| May 22, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $444K · 18,175 sh · 10b5-1 |
| May 22, 2026Form 4 | Taich AdamChief Financial OfficerSold · Class A · $369K · 15,098 sh |
| May 22, 2026Form 4 | Hindson Benjamin J.See Remarks · DirectorSold · Class A · $283K · 11,595 sh |
| Apr 14, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $123K · 5,000 sh · 10b5-1 |
| Mar 24, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $98K · 5,000 sh · 10b5-1 |
| Mar 23, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $191K · 10,000 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $367K · 16,152 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Teichmann Sarah A.DirectorSold · Class A · $147K · 7,579 sh · 10b5-1 |
| Feb 23, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorSold · Class A · $179K · 9,632 sh |
| Feb 23, 2026Form 4 | Taich AdamChief Financial OfficerSold · Class A · $167K · 8,968 sh |
| Feb 23, 2026Form 4 | Hindson Benjamin J.See Remarks · DirectorSold · Class A · $145K · 7,826 sh |
Awards, exercises, withholding and plan purchases · 14 transactions
| Date | Insider |
|---|---|
| Sep 1, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorGift · Class A · $0 · 100 sh |
| Aug 20, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorGift · Class A · $0 · 4,000 sh |
| Jun 4, 2026Form 4 | Kosaraju SridharDirectorAward · Class A · $0 · 8,829 sh |
| Jun 4, 2026Form 4 | MATEO ALANDirectorAward · Class A · $0 · 8,829 sh |
| Jun 4, 2026Form 4 | Popovits Kimberly JDirectorAward · Class A · $0 · 8,829 sh |
| Jun 4, 2026Form 4 | STUELPNAGEL JOHN RDirectorAward · Class A · $0 · 8,829 sh |
| Jun 4, 2026Form 4 | SULIMAN SHEHNAAZDirectorAward · Class A · $0 · 8,829 sh |
| Jun 4, 2026Form 4 | Teichmann Sarah A.DirectorAward · Class A · $0 · 8,829 sh |
| Mar 3, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorGift · Class A · $0 · 2,750 sh · 10b5-1 |
| Feb 26, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorAward · Class A · $0 · 157,895 sh |
| Feb 26, 2026Form 4 | Taich AdamChief Financial OfficerAward · Class A · $0 · 106,579 sh |
| Feb 26, 2026Form 4 | Hindson Benjamin J.See Remarks · DirectorAward · Class A · $0 · 88,816 sh |
| Jan 5, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorExercise or conversion · Class A · $60K · 50,000 sh |
| Jan 5, 2026Form 4 | Saxonov SergeChief Executive Officer · DirectorExercise or conversion · Stock Option (right to buy) · $0 · 50,000 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 10 filings
| Filed | What it is |
|---|---|
| Aug 7, 202610-Q | Quarterly report, Q2 2026 — revenue $151.0M (−13% y/y), net income −$17.9M, EPS −$0.14 |
| Aug 6, 20268-K | Earnings release — EPS −$0.14 vs −$0.23 est. (+39.1%); revenue $151.0M (−13% y/y) 14.1% |
| Jun 8, 20268-K | Shareholder vote results |
| May 8, 202610-Q | Quarterly report, Q1 2026 — revenue $150.8M (−3% y/y), net income −$13.5M, EPS −$0.10 |
| May 7, 20268-K | Earnings release — EPS −$0.10 vs −$0.29 est. (+65.5%); revenue $150.8M (−3% y/y) 3.7% |
| Apr 24, 2026DEFA14A | Additional proxy materials |
| Apr 24, 2026DEF 14A | Proxy statement |
| Feb 13, 202610-K | Annual report, FY2025 — revenue $642.8M (+5% y/y), net income −$43.5M, EPS −$0.35 |
| Feb 12, 20268-K | Earnings release — EPS −$0.13 vs −$0.19 est. (+31.6%); revenue $166.0M (+1% y/y) 3.5% |
| Jan 12, 20268-K | 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 ResultsResults of operations |
2025 · 14 filings
| Filed | What it is |
|---|---|
| Nov 14, 20258-K | Directors or officers; compensation |
| Nov 7, 202510-Q | Quarterly report, Q3 2025 — revenue $149.0M (−2% y/y), net income −$27.5M |
| Nov 6, 20258-K | Earnings release — EPS −$0.22 vs −$0.27 est. (+18.5%); revenue $149.0M (−2% y/y) 17.3% |
| Aug 8, 202510-Q | Quarterly report, Q2 2025 — revenue $172.9M (+13% y/y), net income $34.5M, EPS $0.28 |
| Aug 7, 20258-K | Results of operations |
| Jun 5, 20258-K | Shareholder vote results |
| May 14, 20258-K | Other events |
| May 9, 202510-Q | Quarterly report, Q1 2025 — revenue $154.9M (+10% y/y), net income −$34.4M, EPS −$0.28 |
| May 8, 20258-K | Results of operations; Exit or disposal costs |
| Apr 15, 2025DEFA14A | Additional proxy materials |
| Apr 14, 2025DEF 14A | Proxy statement |
| Feb 13, 202510-K | Annual report, FY2024 — revenue $610.8M (−1% y/y), net income −$182.6M, EPS −$1.52 |
| Feb 12, 20258-K | Results of operations |
| Jan 13, 20258-K | Results of operations |
2024 · 18 filings
| Filed | What it is |
|---|---|
| Oct 29, 202410-Q | Quarterly report, Q3 2024 — revenue $151.7M (−1% y/y), net income −$35.8M, EPS −$0.30 |
| Oct 29, 20248-K | Results of operations; Directors or officers; compensation |
| Oct 9, 20248-K | Results of operations |
| Aug 8, 202410-Q | Quarterly report, Q2 2024 — revenue $153.1M (+4% y/y), net income −$37.9M, EPS −$0.32 |
| Aug 8, 20248-K | Results of operations; Directors or officers; compensation; Other events |
| Jul 11, 20248-K | Directors or officers; compensation |
| Jun 20, 20248-K | Directors or officers; compensation |
| Jun 13, 20248-K | Shareholder vote results |
| Jun 6, 2024DEFA14A | Additional proxy materials |
| Apr 30, 202410-Q | Quarterly report, Q1 2024 — revenue $141.0M (+5% y/y), net income −$59.9M, EPS −$0.50 |
| Apr 30, 20248-K | Results of operations |
| Apr 26, 2024DEFA14A | Additional proxy materials |
| Apr 26, 2024DEF 14A | Proxy statement |
| Apr 12, 2024PRE 14A | Preliminary proxy statement |
| Feb 15, 202410-K | Annual report, FY2023 — revenue $618.7M (+20% y/y), net income −$255.1M, EPS −$2.18 |
| Feb 15, 20248-K | Results of operations |
| Jan 16, 20248-K | Directors or officers; compensation |
| Jan 8, 20248-K | Results of operations |
2023 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202310-Q | Quarterly report, Q3 2023 — revenue $153.6M (+17% y/y), net income −$93.0M, EPS −$0.79 |
| Aug 4, 202310-Q | Quarterly report, Q2 2023 — revenue $146.8M (+28% y/y), net income −$62.4M, EPS −$0.53 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $134.3M (+17% y/y), net income −$50.7M, EPS −$0.44 |
| Apr 28, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023DEF 14A | Proxy statement |
| Feb 16, 202310-K | Annual report, FY2022 — revenue $516.4M (+5% y/y), net income −$166.0M, EPS −$1.46 |
7 current reports (8-K) not listed; the year is on EDGAR.
2022 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202210-Q | Quarterly report, Q3 2022 — revenue $131.1M (+5% y/y), net income −$41.9M, EPS −$0.37 |
| Aug 9, 202210-Q | Quarterly report, Q2 2022 — revenue $114.6M (−1% y/y), net income −$64.5M, EPS −$0.57 |
| May 5, 202210-Q | Quarterly report, Q1 2022 — revenue $114.5M (+8% y/y), net income −$42.4M, EPS −$0.38 |
| Apr 29, 2022DEFA14A | Additional proxy materials |
| Apr 29, 2022DEF 14A | Proxy statement |
| Feb 18, 202210-K | Annual report, FY2021 — revenue $490.5M (+64% y/y), net income −$58.2M, EPS −$0.53 |
7 current reports (8-K) not listed; the year is on EDGAR.
2021 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 5, 202110-Q | Quarterly report, Q3 2021 — revenue $125.3M (+74% y/y), net income −$17.2M, EPS −$0.15 |
| Aug 6, 202110-Q | Quarterly report, Q2 2021 — revenue $115.8M (+170% y/y), net income −$11.1M, EPS −$0.10 |
| May 7, 202110-Q | Quarterly report, Q1 2021 — revenue $105.8M (+47% y/y), net income −$11.6M, EPS −$0.11 |
| Apr 23, 2021DEFA14A | Additional proxy materials |
| Apr 23, 2021DEF 14A | Proxy statement |
| Apr 23, 202110-K/A | Annual report, amended |
| Feb 26, 202110-K | Annual report, FY2020 — revenue $298.8M (+22% y/y), net income −$542.7M, EPS −$5.37 |
7 current reports (8-K) not listed; the year is on EDGAR.
2020 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 12, 202010-Q | Quarterly report, Q3 2020 — revenue $71.8M (+17% y/y), net income −$65.8M, EPS −$0.65 |
| Aug 12, 202010-Q | Quarterly report, Q2 2020 — revenue $42.9M (−23% y/y), net income −$40.2M, EPS −$0.41 |
| May 12, 202010-Q | Quarterly report, Q1 2020 — revenue $71.9M (+34% y/y), net income −$21.1M, EPS −$0.22 |
| Apr 24, 2020DEFA14A | Additional proxy materials |
| Apr 24, 2020DEF 14A | Proxy statement |
| Feb 27, 202010-K | Annual report, FY2019 — revenue $245.9M (+68% y/y), net income −$31.3M, EPS −$0.80 |
11 current reports (8-K) not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 66 filings — 35 × 4, 21 × 144, 6 × SCHEDULE 13G/A and 2 other forms
| Filed | What it is |
|---|---|
| Oct 7, 2026SCHEDULE 13G/A | Other filings |
| Sep 24, 20264 | Insider transaction (Form 4) |
| Sep 24, 20264 | Insider transaction (Form 4) |
| Sep 22, 2026144 | Notice of proposed sale (Form 144) |
| Sep 11, 20264 | Insider transaction (Form 4) |
| Sep 9, 2026144 | Notice of proposed sale (Form 144) |
| Sep 8, 20264 | Insider transaction (Form 4) |
| Sep 8, 2026SCHEDULE 13G | Other filings |
| Sep 3, 20264 | Insider transaction (Form 4) |
| Sep 3, 2026144 | Notice of proposed sale (Form 144) |
| Aug 28, 20264 | Insider transaction (Form 4) |
| Aug 26, 2026144 | Notice of proposed sale (Form 144) |
| Aug 26, 20264 | Insider transaction (Form 4) |
| Aug 26, 20264 | Insider transaction (Form 4) |
| Aug 26, 20264 | Insider transaction (Form 4) |
| Aug 26, 20264 | Insider transaction (Form 4) |
| Aug 24, 2026144 | Notice of proposed sale (Form 144) |
| Aug 24, 2026144 | Notice of proposed sale (Form 144) |
| Aug 24, 2026144 | Notice of proposed sale (Form 144) |
| Aug 24, 2026144 | Notice of proposed sale (Form 144) |
| Aug 24, 20264 | Insider transaction (Form 4) |
| Aug 17, 20264 | Insider transaction (Form 4) |
| Aug 14, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 2026SCHEDULE 13G/A | Other filings |
| Aug 13, 2026144 | Notice of proposed sale (Form 144) |
The newest 25 of 66 shown; the full year is on EDGAR.
2025 · 55 filings — 25 × 4, 14 × SCHEDULE 13G/A, 12 × 144 and 2 other forms
| Filed | What it is |
|---|---|
| Nov 25, 20254 | Insider transaction (Form 4) |
| Nov 25, 20254 | Insider transaction (Form 4) |
| Nov 25, 20254 | Insider transaction (Form 4) |
| Nov 24, 2025144 | Notice of proposed sale (Form 144) |
| Nov 24, 2025144 | Notice of proposed sale (Form 144) |
| Nov 24, 2025144 | Notice of proposed sale (Form 144) |
| Nov 13, 2025SCHEDULE 13G/A | Other filings |
| Nov 5, 2025SCHEDULE 13G/A | Other filings |
| Nov 4, 2025SCHEDULE 13G/A | Other filings |
| Oct 30, 2025SCHEDULE 13G/A | Other filings |
| Oct 27, 2025SCHEDULE 13G/A | Other filings |
| Sep 16, 20254 | Insider transaction (Form 4) |
| Aug 26, 20254 | Insider transaction (Form 4) |
| Aug 26, 20254 | Insider transaction (Form 4) |
| Aug 26, 20254 | Insider transaction (Form 4) |
| Aug 22, 2025144 | Notice of proposed sale (Form 144) |
| Aug 22, 2025144 | Notice of proposed sale (Form 144) |
| Aug 22, 2025144 | Notice of proposed sale (Form 144) |
| Aug 13, 2025SCHEDULE 13G | Other filings |
| Aug 12, 2025SCHEDULE 13G/A | Other filings |
| Aug 7, 2025SCHEDULE 13G/A | Other filings |
| Aug 6, 2025SCHEDULE 13G/A | Other filings |
| Jul 31, 2025SCHEDULE 13G | Other filings |
| Jul 16, 2025SCHEDULE 13G/A | Other filings |
| Jun 11, 20254 | Insider transaction (Form 4) |
The newest 25 of 55 shown; the full year is on EDGAR.
2024 · 55 filings — 29 × 4, 13 × 144, 6 × SC 13G/A and 3 other forms
| Filed | What it is |
|---|---|
| Dec 23, 20244 | Insider transaction (Form 4) |
| Nov 25, 20244 | Insider transaction (Form 4) |
| Nov 25, 20244 | Insider transaction (Form 4) |
| Nov 22, 2024144 | Notice of proposed sale (Form 144) |
| Nov 22, 2024144 | Notice of proposed sale (Form 144) |
| Nov 18, 20244 | Insider transaction (Form 4) |
| Nov 8, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Nov 5, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Oct 4, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Aug 26, 20244 | Insider transaction (Form 4) |
| Aug 26, 20244 | Insider transaction (Form 4) |
| Aug 26, 20244 | Insider transaction (Form 4) |
| Aug 22, 2024144 | Notice of proposed sale (Form 144) |
| Aug 22, 2024144 | Notice of proposed sale (Form 144) |
| Aug 22, 2024144 | Notice of proposed sale (Form 144) |
| Aug 20, 20243 | Initial insider holdings (Form 3) |
| Aug 12, 2024SC 13G | Passive holder above 5% (Schedule 13G) |
| Aug 2, 20244 | Insider transaction (Form 4) |
| Jul 19, 20243 | Initial insider holdings (Form 3) |
| Jun 26, 20243 | Initial insider holdings (Form 3) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
| Jun 13, 20244 | Insider transaction (Form 4) |
The newest 25 of 55 shown; the full year is on EDGAR.
2023 · 65 filings — 45 × 4, 10 × 144, 9 × SC 13G/A and 1 other form
Counted, not listed; the year is on EDGAR.
2022 · 55 filings — 44 × 4, 7 × SC 13G/A, 2 × SC 13G and 2 other forms
Counted, not listed; the year is on EDGAR.
2021 · 117 filings — 103 × 4, 8 × SC 13G/A, 2 × SC 13D/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2020 · 110 filings — 90 × 4, 6 × SC 13G, 4 × SC 13G/A and 9 other forms
Counted, not listed; the year is on EDGAR.
2019 · 61 filings — 15 × 4, 13 × 3, 5 × UPLOAD and 19 other forms
Counted, not listed; the year is on EDGAR.
About this data#
10x Genomics Inc. (TXG) has 694 filings on EDGAR going back to 2019: 8 annual reports, 21 quarterly reports and 65 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 13, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 6, 2026, furnished a press release headed “10x Genomics Reports Second Quarter 2026 Financial Results”. Over the last 13 months insiders sold $16.2M in 26 sales and bought nothing on the open market; 14 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been 10x Genomics Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read TXG's latest 10-K?
- TXG's latest annual report, a 10-K, was filed on Feb 13, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did TXG last file an 8-K?
- On Aug 6, 2026 it furnished a press release headed “10x Genomics Reports Second Quarter 2026 Financial Results”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 6, 2026.
- Are TXG insiders buying or selling?
- Over the last 13 months insiders sold $16.2M in 26 sales and bought nothing on the open market; 14 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Saxonov Serge (Chief Executive Officer · Director) sold 25,000 shares on Sep 22, 2026 for $2.0M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has TXG made?
- 694 filings are on EDGAR under the registrant records that have been 10x Genomics Inc., going back to 2019; 463 of them are insider ownership forms (Forms 3, 4, 5 and 144).